Pattern of drug utilization among hypertensives in a Nigerian teaching hospital

Pharmacoepidemiology and Drug Safety

Volumn 14, Issue 1, 2005, Pages 69-74

  Yusuff, K B ^a   Balogun, O B ^a  

^a UNIVERSITY OF IBADAN   (Nigeria)

Author keywords

Blacks; Blood pressure control; Hypertension; Nigeria; Physician prescribing

Indexed keywords

ACETYLSALICYLIC ACID; AMILORIDE PLUS HYDROCHLOROTHIAZIDE; AMLODIPINE BESYLATE; ANTIHYPERTENSIVE AGENT; ANXIOLYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRISERIN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; GLIBENCLAMIDE; HYDROFLUMETHIAZIDE; IBUPROFEN; INDOMETACIN; LISINOPRIL; MAGNESIUM TRISILICATE; METFORMIN; METHYLDOPA; NAPROXEN; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PIROXICAM; PROPRANOLOL; SPIRONOLACTONE;

ARTICLE; BLOOD PRESSURE REGULATION; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG CLASSIFICATION; DRUG COST; DRUG USE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NIGERIA; OSTEOARTHRITIS; PATIENT COMPLIANCE; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TEACHING HOSPITAL;

ASPIRIN; CROSS-SECTIONAL STUDIES; DIABETES COMPLICATIONS; DIURETICS; DRUG COMBINATIONS; DRUG INTERACTIONS; DRUG UTILIZATION; FEMALE; HOSPITALS, TEACHING; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MALE; NEPHROTIC SYNDROME; NIGERIA; OSTEOARTHRITIS; PATIENT COMPLIANCE; PEPTIC ULCER; PHYSICIANS; RESPIRATION DISORDERS; RETROSPECTIVE STUDIES; SOCIAL WORK; TIME FACTORS;

EID: 11844251324     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.1035     Document Type: Article

References (43)

1. Macmahon S, Peto R, Cutler J, et al. Blood, stroke and coronary artery disease. Part 1, prolonged difference in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-774.
2. Weir MR. How long should we treat blood pressure and why? J Clin Hypertens 1999; 1: 199.
3. Isles CG, Walker LM, Beevers GD, et al. Mortality in patients of the Glasgow Blood Clinic. J Hypertens 1986; 4: 141-156.
4. Lindholm L, Ejlertsson G, Schersten B. High risks of cerebro-vascular morbidity in well treated male hypertensive: a retrospective study of 40-59 years old hypertensives in a Swedish primary care district. Acta Med Scand 1984; 216: 216-259.
5. Burt VL, Cutler JA, Higgins M, et al. Trends in the prevalence, awareness, treatment and control of hypertension in the adult U.S. population. Data from the Health Examination Surveys, 1960 to 1991. Hypertension 1995; 26: 60-69.
6. Colhoun HM, Dong W, Poulter NR. Blood pressure screening, management and control in England: results from the health survey for England. 1994. J Hypertens 1998; 16: 752-757.
7. Murray CJL, Lopez AD (eds). The Global Burden of Diseases, Comprehensive Assessment of Mortality and Disability From Diseases, Injuries and Risk Factors in 1990 Projected to 2020: World Health Organisation. Harvard University Press: USA 1996.
8. Mabadeje AF. WHO-ISH guidelines for the management of hypertension: implementation in Africa-the Nigerian experience. Clin Exp Hypertens 1999; 21(5-6): 671-681.
9. Cooper RS, Rotimi CN, Kaufman SJ, et al. Hypertension treatment and control in Sub-Saharan Africa: the epidemiological basis for policy. Br Med J 1998; 316: 614-617.
10. Olatubosun SK, Kaufman SJ, Cooper RS, et al. Hypertension in black population: prevalence and biosocial determinants of high blood pressure in a group of urban Nigerians. J Hum Hypertens 2000; 14(4): 249-257.
11. Kadiri S, Olutade BO. The clinical presentation of malignant hypertension in Nigerians. J Hum Hypertens 1991; 5(4): 339-343.
12. Kadiri S, Walker O, Salako BL, et al. Blood pressure, hypertension and correlates in urbanised workers in Ibadan: a revisit. J Hum Hypertens 1991; 13(1): 23-27.
13. Soyanwo MO. Issues and non-issues in hypertension in the Nigerian population. Afr J Med Med Sci 2002; 31(2): 179-183.
14. Olubodun JO. Physicians' approach to management of hypertension in a developing community. Int J Cardiol 1995; 51 2): 193-197.
15. Kaufman JS, Rotimi CN, Brieger WR, et al. The mortality risk associated with hypertension: preliminary results of a prospective study in rural Nigerian. J Hum Hypertens 1996; 10(7): 461-464.
16. Amakiri CN, Akang EE, Aghadiuno PU, et al. A prospective study of coroner's autopies in University College Hospital, Ibadan, Nigeria. Med Sci Law 1997; 37(1): 67-75.
17. Kadiri S, Olutade BO, Osobamiro O. Factors influencing the development of malignant hypertension in Nigeria. J Hum Hypertens 2000; 14(3): 159-161.
18. Douglas JG, Bakris GL, Epstein M, et al. Management of high blood pressure in African-Americans: consensus statement of the hypertension in African-American working group of the International Society on Hypertension in Blacks. Arch Int Med 2003; 163 4): 1744-1745.
19. Saunders E. Tailoring treatment to minority patients. Am J Med 1990; 88(3b): 21S-23S.
20. Papademetriou V, Piller LB, Ford CE, ALLHAT Collaborative Group, et al. Major outcomes in high-risk hypertensive patients randomised to angiotensin converting enzyme inhibitor or calcium channel blocker versus Diuretic: the Anti-Hypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288 1981-1997.
21. Lewis PT, Kohner EM, Petrie A, et al. Deterioration of glucose tolerance in hypertensive patients on prolonged diuretic treatment. Lancet 1976; 1: 564-566.
22. Barzilay JI, Piressel S, David BR, for the ALLHAT Collaborative Research Group, et al. Risk and impact of incident glucose disorders in hypertensive older adults treated with an ACE inhibitor, a diuretic or a calcium channel blocker: a report from ALLHAT trial. Am J Hypertens 2004; 17(5 Part 2 of 2): 1A.
23. Modebe O. Erectile failure among medical clinic patients. Afr J Med Med Sci 1990; 19(4): 259-264.
24. Mikhailidis DP, Khan MA, Milionis HJ, et al. The treatment of hypertension in patients with erectile dysfunction. Curr Med Res Opin 2000; 16(1): 31-36.
25. WHO. 2002. Globalisation, diets, and non-communicable diseases. Geneva, Switzerland.
26. Chalmer J, MacMhahon S, Mancia G, et al. WHO-ISH guidelines for management of hypertension. J Hypertens 1999; 17 151-185.
27. Eraker S, Kirscht JP, Becker MH. Understanding and improving compliance. Ann Intern Med 1984; 258-268.
28. German PS, Klein LE. Drug side effects and doctor/patient relationships among elderly patients. J Soc Adm Pharm 1984; 2 67-73.
29. Parati G, Pomidossi G, Albini E. et al. Relationship of 24 hour blood pressure mean and variability to severity of target organ damage in hypertension. Hypertension 1987; 5: 93-98.
30. Lopes AA. Hypertension in black people: pathopyhsiology and therapeutic aspects. J Hum Hypertens 2002; 16(1): S11-S12.
31. Mokwe E, Ohmit SE, Nasser SA, et al. Determinants of blood pressure to quinapril in black and white hypertensive patients: the Quinapril Titration Interval Management Evaluation Trial. Hypertension 2004; 43: 1202-1207.
32. Flack JM, Yunis C, Preisser J, for the ATIME Research Group, et al. The rapidity of drug dose escalation influences blood pressure response and adverse effects in patients with hypertension: Quinapril Titration Interval Management Evaluation (ATIME) Study. Arch Intern Med 2000; 160: 1842-1847.
33. Kizer J, Arnett DK, Bella JN, et al. Differences in left ventricular structure between black and white hypertensive adults: the Hypertensive Genetic Epidemiology Network (Hyper-GEN) Study. Hypertension 2004; 43: 1182-1188.
34. Bild DE, Bluemke DA, Burke GL, et al. Multi-ethnic study of atherosclerosis: objective and design. Am J Epidemiol 2002; 156: 8712-8788.
35. Fenves A, Ram CV. Are angiotensin converting enzyme inhibitors and angiotensin receptor blockers becoming the treatment of choice in Affican-American? Curr Hypertens Rep 2002; 4(4): 286-289.
36. Douglas JG, Agodoa L. ACE inhibiton is effective and renoprotective in hypertensive nephrosclerosis: the African American Study of Kidney Disease and Hypertension (AASK) trial. Kidney Int Suppl 2003; 83: S74-S76.
37. Adigun AQ, Ishola DA, Akintomode AO, et al. Shifting trends in pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real world evaluation of the efficacy, safety, rationality, and pharmacoeconomics of old and new anti-hypertensive drugs. J Hum Hypertens 2003; 17: 277-285.
38. Edwards PR, Steyn K, Walters L, et al. Hypertension management of medical aid patients attending private practises. South Afr Med J 1999; 89(2): 160-164.
39. Anti-Platelet Trialist's Collaboration. Collaborative overview of randomised trials of anti-platelet therapy-1: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308 81-106.
40. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762.
41. American Society of Health-System Pharmacists/American Formulary Service (ASHP/AHFS). AHFS Drug Information. American Society of Health-System Pharmacist, Inc.: Bethesda, U.S.A., 2002: 3030-3031.
42. Askinkugbe OO. Non-communicable diseases, the next epidemic: Nigerians' preparedness. Niger J Clin Pract 2000; 3(2): 17-42.
43. Berthoet N, Fauvat B, Lallab-Stubio CL, et al. Why objective monitoring of compliance is important in management of hypertension. J Clin Hyperten 2000; 2(1): 210-214.